Migraine, Obesity
Conditions
Brief summary
The inhibition of induced dermal blood flow (DBF) responses, before and after rimegepant administration, expressed as the difference in maximal DBF responses (ΔDBF) to capsaicin and electrical stimulation (ES), and stratified for body weight.
Detailed description
Blood: sex steroid levels, rimegepant concentration, CGRP, Body composition parameters: total body weight, total body water (TBW), free mass (FFM), fat mass (FM), soft lean mass (SLM), skeletal muscle mass (SMM), phase angle (PA), Similar outcome measures will be used as described for the primary objective, but stratified for sex steroids, rimegepant concentrations, CGRP and body composition parameters.
Interventions
DRUGRIMEGEPANT
DRUGCapsaicin
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The inhibition of induced dermal blood flow (DBF) responses, before and after rimegepant administration, expressed as the difference in maximal DBF responses (ΔDBF) to capsaicin and electrical stimulation (ES), and stratified for body weight. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood: sex steroid levels, rimegepant concentration, CGRP, Body composition parameters: total body weight, total body water (TBW), free mass (FFM), fat mass (FM), soft lean mass (SLM), skeletal muscle mass (SMM), phase angle (PA), Similar outcome measures will be used as described for the primary objective, but stratified for sex steroids, rimegepant concentrations, CGRP and body composition parameters. | — |
Countries
Netherlands
Outcome results
None listed